Comparison of different silica microporous structures as drug delivery systems for in vitro models of solid tumors

Vilaça, Natália; Machado, Ana Flávia; Morais-Santos, Filipa; Amorim, Ricardo; Neto, Amato; Logodin, Enora; Pereira, M.F.R.; Sardo, Mariana; Rocha, João; Parpot, Píer; Fonseca, A.; Baltazar, Fátima; Neves, Isabel C.

doi:10.1039/c7ra01028a

Cited by 23 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristics of inorganic silica (e.g., size, surface, and topology) can be altered to generate distinct interactions with different types of biological system. Thus, mesoporous silica, amorphous silica, microporous crystalline titanosilicates, and zeolites have been widely used in biomedical applications [4]. The desirable features of mesoporous inorganic materials, more specifically MSNs, are easily tailored to incorporate and interact effectively with an array of poorly soluble drugs and biomolecules.…”

Section: Introductionmentioning

confidence: 99%

Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents

Alyassin

Sayed

Mehta

et al. 2020

Drug Discovery Today

View full text Add to dashboard Cite

Recently, remarkable efforts have focused on research towards enhancing and delivering efficacious and advanced therapeutic agents. Even though this involves significant challenges, innovative techniques and materials have been explored to overcome these. The advantageous properties of mesoporous silica nanoparticles (MSNs), such as unique morphologies and geometries, makes then favorable for use for various drug delivery targeting purposes, particularly in cancer therapy. As we discuss here, MSNs have been utilized over the past few decades to improve the efficiency of anticancer drugs by enhancing their solubility to render them suitable for application, reducing adverse effects, and improving their anticancer cytotoxic efficiency.

show abstract

Section: Introductionmentioning

confidence: 99%

Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents

Alyassin

Sayed

Mehta

et al. 2020

Drug Discovery Today

View full text Add to dashboard Cite

show abstract

“…They are also widely used in the field of drug delivery due to their excellent biocompatibility and the possibility of their mass production with a uniform size and shape. In 2011, the Investigational New Drug Application was first approved by the FDA for clinical trials [ 26 , 27 ].…”

Section: Introductionmentioning

confidence: 99%

Tumor Targeting Effect of Triphenylphosphonium Cations and Folic Acid Coated with Zr-89-Labeled Silica Nanoparticles

et al. 2020

View full text Add to dashboard Cite

In this study, we investigated the tumor targeting effect in cancer cells using triphenylphosphonium (TPP) cations, which are accumulated by differences in membrane potential, and folic acid (FA), which is selectively bound to overexpressed receptors on various cancer cells. We used Food and Drug Administration (FDA)-approved silica nanoparticles (SNPs) as drug carriers, and SNPs conjugated with TPP and FA (STFs) samples were prepared by introducing different amounts of TPP and FA onto the nanoparticle surfaces. STF-1, 2, 3, 4 and 5 are named according to the combination ratio of TPP and FA on the particle surface. To confirm the tumor targeting effect, 89Zr (t1/2 = 3.3 days) was coordinated directly to the silanol group of SNP surfaces without chelators. It was shown that the radiochemical yield was 69% and radiochemical purity was >99%. In the cellular uptake evaluation, SNPs with the most TPP (SFT-5) and FA (SFT-1) attached indicated similar uptake tendencies for mouse colon cancer cells (CT-26). However, the results of the cell internalization assay and measurement of positron emission tomography (PET) images showed that SFT-5 had more affinity for the CT-26 tumor than other samples the TPP ratio of which was lower. Consequently, we confirmed that TPP ligands affect target cancer cells more than FA, which means that cell membrane potential is significantly effective for tumor targeting.

show abstract

“…As can be seen from the abovementioned facts, there are several limitations to the use of 5-FU, thus, encapsulation in an appropriate delivery system might contribute to reduce these side effects and improve its oral bioavailability, preventing its premature degradation and decreasing its side effects, increasing concentrations at the target cell site, with lower cytotoxicity for normal cells. Moreover, encapsulation may allow drugs to be released in a controlled way to the cancer area, preventing degradation of the anticancer drug [29]. Until now, controlled loading and releasing of 5-fluorouracil has been studied from several matrices: organic-modified montmorillonite [30], hybrid TiO 2 /ZnO nanotubes [31], layered inorganic nanocomposites [28], biodegradable polymers [32], hydrogels [33], mesoporous organosilica [34], magnetic nanocarriers [27], porous silica calcium phosphate nanocomposites [35] and zeolites [36,37].…”

Section: Introductionmentioning

confidence: 99%

A Study of 5-Fluorouracil Desorption from Mesoporous Silica by RP-UHPLC

et al. 2019

View full text Add to dashboard Cite

In cancer treatment, the safe delivery of the drug to the target tissue is an important task. 5-fluorouracil (5-FU), the well-known anticancer drug, was encapsulated into the pores of unmodified mesoporous silica SBA-15, as well as silica modified with 3-aminopropyl and cyclohexyl groups. The drug release studies were performed in two different media, in a simulated gastric fluid (pH = 2) and in a simulated body fluid (pH = 7) by RP-UHPLC. The simple and rapid RP-UHPLC method for quantitative determination of 5-fluorouracil released from unmodified and modified mesoporous silica SBA-15 was established on ODS Hypersil C18 column (150 × 4.6 mm, 5 µm) eluted with mobile phase consisted of methanol: phosphate buffer in volume ratio of 3:97 (v/v). Separation was achieved by isocratic elution. The flow rate was kept at 1 mL/min, the injection volume was set at 20 µL and the column oven temperature was maintained at 25 °C. The effluent was monitored at 268 nm. This paper provides information about the quantitative determination of the released 5-FU from silica. It was found out that larger amount of the drug was released in neutral pH in comparison with the acidic medium. In addition, surface functionalisation of silica SBA-15 influences the release properties of the drug.

show abstract

Comparison of different silica microporous structures as drug delivery systems for in vitro models of solid tumors

Abstract: 5-FU release profiles reveled to be dependent on the host structures. 5-FU DDS led to significant potentiation of the 5-FU effect in cancer cells.

Cited by 23 publications

References 39 publications

Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents

Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents

Tumor Targeting Effect of Triphenylphosphonium Cations and Folic Acid Coated with Zr-89-Labeled Silica Nanoparticles

A Study of 5-Fluorouracil Desorption from Mesoporous Silica by RP-UHPLC

Contact Info

Product

Resources

About